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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
L-carnitine and faster recovery from muscle fatigue after exercise (ID 738, 
1492, 1493), skeletal muscle tissue repair (ID 738, 1492, 1493), increase in 
endurance capacity (ID 4305, 4684), maintenance of normal blood 
LDL-cholesterol concentrations (ID 1494, 4684), contribution to normal 
spermatogenesis (ID 1822), “energy metabolism” (ID 1821), and increasing 
L-carnitine concentrations and/or decreasing free fatty acids in blood 
during pregnancy (ID 1495) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific output, published on 14 July 2011, replaces the earlier version published on 30 June 
2011
4
.  
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to L-carnitine and faster recovery from muscle fatigue after exercise, skeletal muscle tissue 
repair, increase in endurance capacity, maintenance of normal blood LDL-cholesterol concentrations, 
contribution to normal spermatogenesis, “energy metabolism”, and increasing L-carnitine 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1525, EFSA-Q-2008-2229, EFSA-Q-2008-2230, 
EFSA-Q-2008-2231, EFSA-Q-2008-2232, EFSA-Q-2008-2554, EFSA-Q-2008-2555, EFSA-Q-2010-00258, EFSA-Q-
2010-00637, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette 
Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens. 
4  After publication of this opinion, the conclusion section of the opinion has been amended in order to reflect the 
conclusions of the NDA Panel as outlined in the main text of the opinion. Where changes have been made to the text of the 
opinion footnotes have been included to indicate the changes. 
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concentrations and/or decreasing free fatty acids in blood during pregnancy. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food constituent that is the subject of the health claims is carnitine (as L-carnitine). The Panel 
considers that L-carnitine is sufficiently characterised.  
Faster recovery from muscle fatigue after exercise  
The claimed effects are “fat metabolism” and “muscle metabolism/recovery after exercise”. The target 
population is assumed to be adults performing strenuous exercise. In the context of the proposed 
wordings, the Panel assumes that the claimed effects refer to recovery from muscle fatigue after 
exercise. The Panel considers that faster recovery from muscle fatigue after exercise is a beneficial 
physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-carnitine and faster recovery from muscle fatigue 
after exercise.  
Skeletal muscle tissue repair  
The claimed effects are “fat metabolism” and “muscle metabolism/recovery after exercise”. The target 
population is assumed to be adults performing resistance exercise. In the context of the proposed 
wordings, the Panel assumes that the claimed effects refer to the rebuilding of structural protein 
within the skeletal muscle tissue after exercise which has caused muscle damage. The Panel considers 
that skeletal muscle tissue repair is a beneficial physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-carnitine and skeletal muscle tissue repair.  
Increase in endurance capacity  
The claimed effects are “ergogenic role in sports and exercise”, and “fat metabolism by mediating the 
transport of long-chain fatty acids across the inner mitochondrial membrane”. The target population is 
assumed to be adults performing endurance exercise. In the context of the proposed wordings, the 
Panel assumes that the claimed effects refer to an increase in endurance capacity by promoting fat 
oxidation. The Panel considers that an increase in endurance capacity is a beneficial physiological 
effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between consumption of L-carnitine and increase in endurance capacity.  
Maintenance of normal blood LDL-cholesterol concentrations 
The claimed effects are “heart health” and “fat metabolism by mediating the transport of long-chain 
fatty acids across the inner mitochondrial membrane”. The target population is assumed to be the 
general population. In the context of the proposed wordings, the Panel assumes that the claimed 
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effects refer to the maintenance of normal blood LDL-cholesterol concentrations. The Panel considers 
that maintenance of normal blood LDL-cholesterol concentrations is a beneficial physiological effect. 
In weighing the evidence, the Panel took into account that the human intervention studies provided 
did not show a sustained effect of L-carnitine consumption on blood cholesterol concentrations, that 
results from studies in rats and rabbits cannot be extrapolated to humans because of major differences 
in lipid metabolism between species, and that no evidence for a mechanism by which L-carnitine 
could exert the claimed effect in humans has been provided.  
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-carnitine and maintenance of normal blood 
LDL-cholesterol concentrations. 
Contribution to normal spermatogenesis  
The claimed effect is “sexual organs, hormone activity”. The target population is assumed to be the 
general male population. In the context of the proposed wordings, the Panel assumes that the claimed 
effect refers to contribution to normal spermatogenesis. The Panel considers that contribution to 
normal spermatogenesis is a beneficial physiological effect. 
No human studies were provided from which conclusions could be drawn for the scientific 
substantiation of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-carnitine and contribution to normal spermatogenesis. 
“Energy metabolism” 
The claimed effect is “energy metabolism”. The target population is assumed to be the general 
population. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
Increasing L-carnitine concentrations and/or decreasing free fatty acids in blood during 
pregnancy 
The claimed effect is “pregnancy”. The target population is assumed to be pregnant women. In the 
context of the proposed wordings, the Panel assumes that the claimed effect relates to increasing 
L-carnitine concentrations and decreasing in free fatty acids in blood during pregnancy. The Panel 
considers that the evidence provided does not establish that increasing L-carnitine concentrations 
and/or decreasing free fatty acids in blood during pregnancy in the context of a protein adequate diet 
is a beneficial physiological effect per se. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of L-carnitine and a beneficial physiological effect related 
to increasing L-carnitine concentrations and/or decreasing free fatty acids in blood during pregnancy. 
KEY WORDS 
L-Carnitine, fatigue, skeletal muscle, endurance capacity, spermatogenesis, pregnancy, fatty acids, energy 
metabolism, health claims.  
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
5
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
6
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is carnitine (as L-carnitine).  
Carnitine is a quaternary ammonium salt synthesised primarily in the liver and kidneys from amino 
acids, lysine and methionine. In living cells carnitine is required for the transport of fatty acids from 
the cytosol into the mitochondria for beta-oxidation. L-carnitine is the form commonly used in food 
supplements. The content of L-carnitine in foods can be measured by established methods. This 
opinion refers to the effects of L-carnitine when consumed as food supplements in addition to a 
protein adequate diet.  
The Panel considers that the food constituent, L-carnitine, which is the subject of the health claims, is 
sufficiently characterised.  
2. Relevance of the claimed effect to human health 
2.1. Faster recovery from muscle fatigue after exercise (ID 738, 1492, 1493) 
The claimed effects are “fat metabolism” and “muscle metabolism/recovery after exercise”. The Panel 
assumes that the target population is adults performing strenuous exercise. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to recovery 
from muscle fatigue after exercise. 
Fatigue can be defined as the loss of peak force or power output. Therefore, muscle fatigue recovery 
can be defined as the regain of maximal muscle strength or muscle power after performance of 
strenuous exercise which has induced muscle fatigue. 
The Panel considers that faster recovery from muscle fatigue after exercise is a beneficial 
physiological effect. 
                                                     
5  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
6  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2.2. Skeletal muscle tissue repair (ID 738, 1492, 1493) 
The claimed effects are “fat metabolism” and “muscle metabolism/recovery after exercise”. The Panel 
assumes that the target population is adults performing resistance exercise. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
rebuilding of structural protein within the skeletal muscle tissue after exercise which has caused 
muscle damage.  
The Panel considers that skeletal muscle tissue repair is a beneficial physiological effect. 
2.3. Increase in endurance capacity (ID 4305, 4684) 
The claimed effects are “ergogenic role in sports and exercise”, and “fat metabolism by mediating the 
transport of long-chain fatty acids across the inner mitochondrial membrane”. The Panel assumes that 
the target population is adults performing endurance exercise. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in endurance capacity by promoting fat oxidation. Endurance capacity refers to the exercise 
time to self-reported fatigue when exercising at a constant workload or speed.  
The Panel considers that an increase in endurance capacity is a beneficial physiological effect. 
2.4. Maintenance of normal blood LDL-cholesterol concentrations (ID 1494, 4684) 
The claimed effects are “heart health” and “fat metabolism by mediating the transport of long-chain 
fatty acids across the inner mitochondrial membrane”. The Panel assumes that the target population is 
the general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance of normal blood LDL-cholesterol concentrations. 
Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the 
normal structure and function of the arteries. 
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
2.5. Contribution to normal spermatogenesis (ID 1822) 
The claimed effect is “sexual organs, hormone activity”. The Panel assumes that the target population 
is the general male population.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to 
contribution to normal spermatogenesis. 
The Panel considers that contribution to normal spermatogenesis is a beneficial physiological effect. 
2.6. “Energy metabolism” (ID 1821) 
The claimed effect is “energy metabolism”. The Panel assumes that the target population is the 
general population. 
L-Carnitine related health claims 
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The claimed effect is not sufficiently defined, and no further details were given in the proposed 
wordings. No clarifications have been provided by Member States. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
2.7. Increasing L-carnitine concentrations and/or decreasing free fatty acids in blood 
during pregnancy (ID 1495) 
The claimed effect is “pregnancy”. The Panel assumes that the target population is pregnant women. 
In the context of the proposed wordings, the Panel assumes that the claimed effect relates to 
increasing L-carnitine concentrations, and to decreasing free fatty acids, in blood during pregnancy.  
The Panel considers that the evidence provided does not establish that increasing L-carnitine 
concentrations and/or decreasing free fatty acids in blood during pregnancy in the context of a protein 
adequate diet is a beneficial physiological effect per se. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-carnitine and a beneficial physiological effect related to increasing L-carnitine 
concentrations and/or decreasing free fatty acids in blood during pregnancy. 
3. Scientific substantiation of the claimed effect 
3.1. Faster recovery from muscle fatigue after exercise (ID 738, 1492, 1493) 
The references provided in relation to this claim included a number of narrative reviews, commentary 
papers, textbook chapters and animal studies. These references were either on food constituents (e.g. 
L-propionylcarnitine, and a combination of caffeine, carnitine and choline) unrelated to the food 
constituent which is the subject of the claim, or addressed outcomes (e.g. fatty acid oxidation, and 
muscle pain) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claim.  
One reference reporting on a pilot human intervention study on the effects of L-carnitine 
supplementation on muscle recovery after exercise in six trained and six untrained subjects was 
provided as a symposium report. The report contained insufficient information regarding 
randomisation and statistical analyses for a full scientific evaluation (Maggini et al., 2000). The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim.  
The Panel concludes that a cause and effect relationship has not been established between 
consumption of L-carnitine and faster recovery from muscle fatigue after exercise.  
3.2. Skeletal muscle tissue repair (ID 738, 1492, 1493) 
The references provided in relation to this claim included a number of narrative reviews, commentary 
papers, textbook chapters and animal studies. These references were either on food constituents (e.g. 
L-propionylcarnitine, and a combination of caffeine, carnitine and choline) unrelated to the food 
constituent which is the subject of the claim, or addressed outcomes (e.g. fatty acid oxidation, and 
muscle pain) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claim.  
L-Carnitine related health claims 
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No references were provided which assessed the effects of L-carnitine consumption on muscle tissue 
repair after exercise.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-carnitine and skeletal muscle tissue repair.  
3.3. Increase in endurance capacity (ID 4305, 4684) 
The references provided in relation to the claim included narrative reviews and human studies which 
addressed outcomes (e.g. fatty acid oxidation, protein turnover, body weight and cardiac disorders) 
unrelated to the claimed effect. 
One uncontrolled, open label human intervention study investigated the effect of L-carnitine 
supplementation (2 g/day for six weeks) on endurance capacity assessed using progressive treadmill 
tests until exhaustion in seven elite male marathon runners (Swart et al., 1997). The Panel notes the 
uncontrolled nature of the study, and considers that no conclusions can be drawn from this study for 
the scientific substantiation of the claim.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-carnitine and increase in endurance capacity.  
3.4. Maintenance of normal blood LDL-cholesterol concentrations (ID 1494, 4684) 
Some of the references provided were narrative reviews, and human, animal and in vitro studies, 
which reported on health outcomes (e.g. therapeutic efficacy in acute myocardial infarction, 
congestive heart failure and post-infarction; markers of recovery after exercise; electrocardiogram 
changes during exercise; delayed muscle pain after eccentric effort; long-chain fatty acid oxidation; 
protein turnover; glutathione redox state and mitochondrial enzymes in muscle and heart tissue) 
unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
Seven human intervention studies which investigated the effect of L-carnitine consumption on blood 
lipids were provided. 
El-Metwally et al. (2003) and Vesela et al. (2001) assessed the effect of L-carnitine consumption on 
blood lipids in 24 children with chronic renal failure undergoing long-term haemodialysis, and in 12 
dialysed adult patients, respectively. The Panel considers that the evidence provided does not 
establish that patients with chronic renal failure undergoing haemodialysis are representative of the 
general population with regard to blood lipids and lipid metabolism, and that the results obtained in 
these studies with respect to changes in LDL-cholesterol concentrations cannot be extrapolated to the 
general population. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim. 
In a one arm study (Stefanutti et al., 1998), the effect of L-carnitine consumption (3x1 g daily) on 
blood lipids was assessed in 24 subjects (aged 39-64 years) on a diet aiming to reduce blood 
cholesterol concentrations. The Panel notes the lack of a control group and considers that no 
conclusions can be drawn from this uncontrolled study for the scientific substantiation of the claim. 
One parallel, randomised intervention study (Digiesi et al., 1994) in 37 subjects (mean age 60 years) 
with essential hypertension examined the effect of L-carnitine and antihypertensive medication on 
total cholesterol concentrations among other variables. Subjects received antihypertensive medication 
plus 2 g L-carnitine per day (group A1), antihypertensive medication only (group A2) or L-carnitine 
only (2 g/day, group B). Subjects in groups A1 and A2 (n=28) followed the intervention for 22 weeks, 
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and subjects in group B (n=9) for 10 weeks. The Panel notes the lack of a direct statistical comparison 
between the study groups, and thus the uncontrolled nature of the study, and considers that no 
conclusions can be drawn from this uncontrolled study for the scientific substantiation of the claim. 
In a randomised, double-blind, placebo-controlled study with a parallel design (Pistone et al., 2003) 
84 subjects (aged 70-92 years) with onset of fatigue after slight physical exercise were recruited to 
receive either L-carnitine (2x2 g/day, n=42) or placebo (n=42) for 30 days following a 2-week run-in 
phase in which subjects had followed a National Cholesterol Education Program (NCEP) Step 2 diet. 
All analyses were performed in the intent-to-treat population. In the L-carnitine group, total and 
LDL-cholesterol concentrations significantly decreased compared to placebo (-1.2 vs. +0.1 mmol/L, 
and -1.1 vs. -0.2 mmol/L, respectively, p<0.01). Total fat mass and total muscle mass also changed 
significantly in the L-carnitine compared to the placebo group (-3.1 vs. -0.5 kg and +2.1 vs. +0.2 kg, 
respectively, p<0.01). The Panel notes that this study showed an effect of L-carnitine on total and 
LDL-cholesterol concentrations when L-carnitine was consumed for 30 days. However, the Panel also 
notes that the constituents of the placebo were not reported, and that the study duration does not allow 
conclusions to be drawn on the sustainability of the effect.  
In a double-blind, placebo-controlled intervention (Sirtori et al., 2000), 36 hyperlipidaemic subjects 
(mean age 55.9±9.3 years) with plasma Lp(a) ranging between 40 and 80 mg/dL and on isocaloric 
diets with a ratio of polyunsaturated/saturated fatty acids of 1.0 for the management of 
hyperlipidaemia were randomised to receive either L-carnitine (2 g/day, n=18) or placebo (n=18) for 
12 weeks. Twelve subjects were taking low-dose acetylsalicylic acid and were on antihypertensive 
therapy, and eight subjects had either suffered from a myocardial infarction, had a transient ischaemic 
attack, or had stable angina or intermittent claudication and were taking medication (not specified) for 
these conditions. No statistically significant changes in total, LDL- or HDL-cholesterol concentrations 
were observed between groups. No body weight changes were observed during the study. The Panel 
notes that no information was provided on drop-outs during the study, or on the medication taken by 
some subjects. The Panel also notes that this study does not show an effect of L-carnitine on total, 
LDL- or HDL-cholesterol concentrations. 
In a double-blind, placebo-controlled intervention study with a parallel design (Derosa et al., 2003), 
94 hypercholesterolaemic subjects (mean age 51±6.5 years) with newly diagnosed type 2 diabetes 
mellitus managed with diet only were randomised after a 4-week placebo wash-out period to receive 
either L-carnitine (2x1 g/day, n=46) or placebo (n=48) for six months. Sixteen subjects were taking 
low-dose acetylsalicylic acid and were on antihypertensive therapy. Subjects were instructed to follow 
a standardised diet providing 1,400 to 1,600 kcal/day (55 % carbohydrates, 25 % proteins, 20 % fat, 
of which <7 % saturated fat), 105 mg cholesterol and 36 g fibre, and to perform aerobic exercise for at 
least 30 minutes on three to four days per week. Sample size calculations were not reported. It is 
unclear whether per protocol or intention-to-treat analyses were performed. No statistically significant 
changes in total or LDL-cholesterol concentrations were observed between groups. Body weight and 
BMI did not change significantly during the study in either group. The Panel notes that this study does 
not show an effect of L-carnitine on total or LDL-cholesterol concentrations. 
The Panel notes that although one short-term human intervention study (30 days) reported a 
significant effect of L-carnitine consumption on the reduction of total and LDL-cholesterol 
concentrations, two human intervention studies of longer duration (12 weeks and six months, 
respectively) did not show an effect. The Panel considers that the human intervention studies provided 
did not show a sustained effect of L-carnitine consumption on blood cholesterol concentrations.  
Two animal studies in rats (Mondola et al., 1988) and rabbits (Diaz et al., 2000) reported on the 
effects of L-carnitine on plasma lipoproteins and the apolipoprotein pattern. The Panel considers that 
results from studies in rats and rabbits cannot be extrapolated to humans because of major differences 
in lipid metabolism between species.  
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The Panel notes that no evidence for a plausible mechanism by which L-carnitine could exert the 
claimed effect in humans has been provided. 
In weighing the evidence, the Panel took into account that the human intervention studies provided 
did not show a sustained effect of L-carnitine consumption on blood cholesterol concentrations, that 
results from studies in rats and rabbits cannot be extrapolated to humans because of major differences 
in lipid metabolism between species, and that no evidence for a mechanism by which L-carnitine 
could exert the claimed effect in humans has been provided.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-carnitine and maintenance of normal blood LDL-cholesterol concentrations. 
3.5. Contribution to normal spermatogenesis (ID 1822)  
Most of the references provided were not related to the food constituent which is the subject of the 
claim. One narrative review on sperm quality did not provide any original data for the substantiation 
of the claim. The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claim. 
One animal study examined the effect of L-carnitine on testicular ischaemic reperfusion injury in rats 
(Dokmeci et al., 2007). The Panel considers that evidence provided in animal studies is not sufficient 
to predict the occurrence of an effect of L-carnitine consumption on spermatogenesis in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of L-carnitine and contribution to normal spermatogenesis. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, L-carnitine, which is the subject of the health claims, is sufficiently 
characterised.  
Faster recovery from muscle fatigue after exercise (ID 738, 1492, 1493) 
 The claimed effects are “fat metabolism” and “muscle metabolism/recovery after exercise”. 
The target population is assumed to be adults performing strenuous exercise. In the context of 
the proposed wordings, it is assumed that the claimed effects refer to recovery from muscle 
fatigue after exercise. Faster recovery from muscle fatigue after exercise is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-carnitine and faster recovery from muscle fatigue after exercise.  
Skeletal muscle tissue repair (ID 738, 1492, 1493) 
 The claimed effects are “fat metabolism” and “muscle metabolism/recovery after exercise”. 
The target population is assumed to be adults performing resistance exercise. In the context of 
the proposed wordings, it is assumed that the claimed effects refer to the rebuilding of 
structural protein within the skeletal muscle tissue after exercise which has caused muscle 
damage. Skeletal muscle tissue repair is a beneficial physiological effect. 
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 A cause and effect relationship has not been established between the consumption of 
L-carnitine and skeletal muscle tissue repair.  
Increase in endurance capacity (ID 4305, 4684) 
 The claimed effects are “ergogenic role in sports and exercise”, and “fat metabolism by 
mediating the transport of long-chain fatty acids across the inner mitochondrial membrane”. 
The target population is assumed to be adults performing endurance exercise. In the context 
of the proposed wordings, it is assumed that the claimed effects refer to an increase in 
endurance capacity by promoting fat oxidation. An increase in endurance capacity is a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-carnitine and increase in endurance capacity
7
.  
Maintenance of normal blood LDL-cholesterol concentrations (ID 1494, 4684) 
 The claimed effects are “heart health” and “fat metabolism by mediating the transport of 
long-chain fatty acids across the inner mitochondrial membrane”. The target population is 
assumed to be the general population. In the context of the proposed wordings, it is assumed 
that the claimed effects refer to the maintenance of normal blood LDL-cholesterol 
concentrations. Maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
L-carnitine and maintenance of normal blood LDL-cholesterol concentrations. 
Contribution to normal spermatogenesis (ID 1822) 
 The claimed effect is “sexual organs, hormone activity”. The target population is assumed to 
be the general male population. In the context of the proposed wordings, it is assumed that the 
claimed effect refers to contribution to normal spermatogenesis. Contribution to normal 
spermatogenesis is a beneficial physiological effect.  
 A cause and effect relationship has not been established between the consumption of 
L-carnitine and contribution to normal spermatogenesis. 
“Energy metabolism” (ID 1821) 
 The claimed effect is “energy metabolism”. The target population is assumed to be the 
general population. 
 The claimed effect is general and non-specific, and does not refer to any specific health claim 
as required by Regulation (EC) No 1924/2006. 
Increasing L-carnitine concentrations and/or decreasing free fatty acids in blood during 
pregnancy (ID 1495) 
 The claimed effect is “pregnancy”. The target population is assumed to be pregnant women. 
The evidence provided does not establish that increasing L-carnitine concentrations and/or 
decreasing free fatty acids in blood during pregnancy in the context of a protein adequate diet 
is a beneficial physiological effect per se.  
                                                     
7  Original text: “A cause and effect relationship has not been established between the consumption of L-carnitine and 
skeletal muscle tissue repair” and “skeletal muscle tissue repair” has been replaced with “increase in endurance capacity”. 
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 A cause and effect relationship has not been established between the consumption of 
L-carnitine and a beneficial physiological effect related to increasing L-carnitine 
concentrations and/or decreasing free fatty acids in blood during pregnancy. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1525, 
EFSA-Q-2008-2229, EFSA-Q-2008-2230, EFSA-Q-2008-2231, EFSA-Q-2008-2232, EFSA-Q-2008-
2554, EFSA-Q-2008-2555, EFSA-Q-2010-00258, EFSA-Q-2010-00637). The scientific substantiation 
is based on the information provided by the Member States in the consolidated list of Article 13 
health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
8
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
9
  
Foods are commonly involved in many different functions
10
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
8 OJ L12, 18/01/2007 
9 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
10 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to L-carnitine, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
738 Carnitine. Fat metabolism. Helps the energy production in the 
cell by transporting fatty acids in 
places where they are used and 
metabolised/contributes to the fat 
burning during 
exercise/contributes to increased 
fat oxidation/is important for the 
oxidation of fat/helps improve 
muscle recovery after 
exercise/helps mantain optimal 
repair of muscle tissue/transports 
long-chain fatty acids into the 
mitocondria/plays an important 
role in lipid metabolism/can 
support lipid metabolism converts 
fatty acids into energy/turns fat 
into energy/helps to increase fatty 
acid oxidation in healty humans. 
Conditions of use 
- Max 200 mg per day 
ID Food or Food constituent Health Relationship Proposed wording 
1492 Carnitine. Fat metabolism. Helps the energy production in the 
cell by transporting fatty acids in 
places where they are used and 
metabolised 
-contributes to the fat burning 
during exercise 
-contributes to increased fat 
oxidation 
-is important for the oxidation of 
fat 
-helps improve muscle recovery 
after exercise 
-helps maintain optimal repair of 
muscle tissue 
-plays an important role in lipid 
metabolism 
-can support lipid metabolism 
converts fatty acids into energy 
-helps to increase fatty acid 
oxidation in healthy humans 
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Conditions of use 
- Erwachsene - Amount of consumption: 250 Milligramm (mg), 250-3500. Period of 
consumption: 14-30 Tage. Upper limit (value): 8000 Milligramm (mg). 
- Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or 
other substance: Presence of a nutrient or other substance. Number of nutrients/other 
substances that are essential to claimed effect: 4. Names of nutrient/other substances and 
Quantity in Average daily serving: 20mg Carnitine, 300mg Garcinia Cambogia, 50mg CLA, 
66 micrograms Chromium Polynicotinate. Weight of average daily food serving: 60 
miligram(s). Daily amount to be consumed to produce claimed effect: 400 miligram(s). 
Number of food portions this equates to in everyday food portions: 3. Are there factors that 
could interfere with bioavailability: Yes. Please give reason: do not store above 25 degrees 
C. Length of time after consumption for claimed effect to become apparent: It is apparent 
after a period of regular use.  Number of days: 14. Is there a limit to the amount of food 
which should be consumed in order to avoid adverse health effects: Don't Know. 
- 200 mg/Tag. 
- bis 1000 mg pro Tag. 
- bis 250 mg pro Tag. 
- Tagesdosis: 500 mg. 
- 0,2 g pro Tag. 
- Sportler. 
- Min 200 mg per day; 100-500mg per day. 
- L-karnitiini sisaldus varieerub: 200 mg/100 g; 400 mg/100 g; 600 mg/100 g. 
- Ausdauersport–Tagesdosis ab 500 mg–L-Carnitin. Tagesdosis ab ca. 1 g–Erwachsene. 
ID Food or Food constituent Health Relationship Proposed wording 
1493 Carnitine. Muscle metabolism / 
Recovery after exercise. 
Helps improve muscle recovery 
after exercise 
-helps maintain optimal repair of 
muscle tissue 
-supports athletes in recovery from 
weight training 
-can help recreationally weight-
trained in recovery from exercise 
-contributes to the reduction of 
muscle soreness from exercise in 
trained athletes 
Conditions of use 
- 200 mg/Tag; Upper limit (value): 500 mg. 
- Drink with 400mg/serving of L-carnitine. 
- 30 mg, (15% of the average daily intake 200 mg). 
- A minimum of 200-500 mg per day. 100-500mg per day. A minimum of 2g per day is 
required. 
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ID Food or Food constituent Health Relationship Proposed wording 
1494 Carnitine. Heart health. Helps to maintain healthy blood 
cholesterol and plasma lipid levels 
in the elderly. 
Conditions of use 
- Erwachsene - 250 - 1.000 Milligramm (mg). 
- 200 mg/Tag. 
- Food supplement with 100 mg of L-carnitine in the daily dose. 
- Min 200 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
1495 Carnitine. Pregnancy. Can increase L-Carnitine levels 
during pregnancy and lactation. 
Can help decrease free fatty acids 
during pregnancy. 
Can maintain normal L-Carnitine 
plasma levels during pregnancy. 
Conditions of use 
- Schwangere - 500mg/Tag. 
- Min. 500 mg/day. 
ID Food or Food constituent Health Relationship Proposed wording 
1821 L-carnitine. Energy metabolism. Makes energy metabolism more 
effective. 
Protects cell energy metabolism. 
Reduces changes in energy 
metabolism caused by ageing. 
Conditions of use 
- Food supplement with 100mg of L-carnitine in the daily dose. 
 Comments from Member States 
No further clarification received. 
ID Food or Food constituent Health Relationship Proposed wording 
1822 L-carnitine. Sexual organs, hormone 
activity 
Improves sperm quality. 
Conditions of use 
- Food supplement with 100mg of L-carnitine in the daily dose. 
- 1500 mg L-arginine per day. 
ID Food or Food constituent Health Relationship Proposed wording 
4305 Carnitine. ERGOGENIC role in sports 
and exercise. 
Helps to delay the onset of fatigue. 
Helps to maintain energy levels 
for prolonged periods during 
intense competition/exercise. 
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Enhances endurance and helps to 
maintain peak effort during times 
of high physical demand. 
Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Sports foods 
and food supplements providing minimum of 200-500mg carnitine per recommended daily 
consumption. 
ID Food or Food constituent Health Relationship Proposed wording 
4684 L/carnitine. Fat metabolism by 
mediating the transport of 
long-chain fatty acids 
across the inner 
mitochondrial membrane. 
Helps burn fat faster and thus 
improves physical performance. / 
Helpful in decreasing the LDL-
colesterol level / Helpful in 
decreasing colesterol’s blood 
levels / In diets, supplemented by 
a food diet and phisical exercices.  
/ Accelerate the fatty acid import 
into mitochondria, which leads to 
a faster oxidation, favoring an 
efficient weight decrease as well 
as increasing of  effort resistance. 
Conditions of use 
- 300 - 1200 mg/day. 
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GLOSSARY AND ABBREVIATIONS 
BMI  Body mass index 
ECG  Electrocardiogram 
HDL  High-density lipoproteins 
LDL  Low-density lipoproteins 
 
 
